Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: Real-life data from a large healthcare maintenance organisation

Heart

Volumn 98, Issue 24, 2012, Pages 1817-1821

  Rabinowich, Liane ^a   Steinvil, Arie ^b   Leshem Rubinow, Eran ^b   Berliner, Shlomo ^a   Zeltser, David ^a   Rogowski, Ori ^a   Shalev, Varda ^c   Raz, Raanan ^c   Chodick, Gabriel ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; VENOUS THROMBOEMBOLISM;

COLORING AGENTS; FEMALE; FOLLOW-UP STUDIES; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INCIDENCE; ISRAEL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; PROGNOSIS; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 84870459912     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302906     Document Type: Article

References (30)

1. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006;4:1886-90. (Pubitemid 44226763)
2. Linnemann B, Zgouras D, Schindewolf M, et al. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis 2008;19:159-65. (Pubitemid 351252995)
3. Braekkan SK, Mathiesen EB, Njolstad I, et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J Thromb Haemost 2008;6:1851-7.
4. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010;103:56-61.
5. Steffen LM, Folsom AR, Cushman M, et al. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Circulation 2007;115:188-95. (Pubitemid 46105717)
6. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-61.
7. Squizzato A, Galli M, Romualdi E, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010;31:1248-56.
8. Ramcharan AS, Van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009;7:514-20.
9. Sorensen HT, Horvath-Puho E, Sogaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009;7:521-8.
10. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;161:1405-10. (Pubitemid 32681161)
11. Pai M, Evans NS, Shah SJ, et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011;128:422-30.
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97. (Pubitemid 41127293)
13. Hippisley-Cox J, Coupland C. Individualising the risks of statins in men and women in England and Wales: population-based cohort study. Heart 2010;96:939-47.
14. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61. (Pubitemid 34787476)
15. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169:260-8.
16. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62. (Pubitemid 28228203)
17. Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 2011;124:852-9.
18. Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 2002;53:101-5. (Pubitemid 34117746)
19. Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109.
20. Freeman DJ, Robertson M, Brown EA, et al. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatr 2011;11:8.
21. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
22. Agarwal V, Phung OJ, Tongbram V, et al. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int J Clin Pract 2010;64:1375-83.
23. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102. (Pubitemid 350301144)
24. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010;121:1896-903.
25. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004;18:477-82. (Pubitemid 39215361)
26. Thomsen RW. The lesser known effects of statins: benefits on infectious outcomes may be explained by 'healthy user' effect. BMJ 2006;333:980-1. (Pubitemid 44764341)
27. LaFleur J, Nelson RE, Sauer BC, et al. Overestimation of the effects of adherence on outcomes: a case study in healthy user bias and hypertension. Heart 2011;97:1862-9.
28. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-79.
29. Abughosh SM, Kogut SJ, Andrade SE, et al. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm 2004;10:404-11.
30. Shalev V, Goldstein I, Porath A, et al. Persistence with statins and reduction of low density lipoprotein cholesterol: analysis of real-life data from community settings. Pharmacoepidemiology and Drug Safety 2012;21(suppl. 3):270.